Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
19.09. | Maze Therapeutics, Inc. (MAZE): A Bull Case Theory | 17 | Insider Monkey | ||
15.09. | Maze Therapeutics stock price target raised to $34 at Guggenheim on promising PKU data | 3 | Investing.com | ||
15.09. | Maze Therapeutics: Guggenheim erhöht Kursziel nach vielversprechenden PKU-Studiendaten deutlich auf 34 $ | 1 | Investing.com Deutsch | ||
14.09. | Maze Therapeutics Drug Shows Potential to Top Asset Acquired by Otsuka for $800M | 4 | MedCity News | ||
12.09. | Doppeltes Potenzial treibt Aktie an: H.C. Wainwright hebt Kursziel für Maze Therapeutics deutlich an | 2 | Investing.com Deutsch | ||
MAZE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
12.09. | Maze Therapeutics stock jumps as H.C. Wainwright raises price target on dual potential | 1 | Investing.com | ||
11.09. | Maze Therapeutics stock price target raised to $37 at BTIG on strong data | 1 | Investing.com | ||
11.09. | Maze Therapeutics, Opendoor Technologies, Oxford Industries, VNET Group And Other Big Stocks Moving Higher On Thursday | 3 | Benzinga.com | ||
11.09. | Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results | 5 | Investor's Business Daily | ||
11.09. | Maze Therapeutics climbs after early-stage trial data for rare disease drug | 7 | Seeking Alpha | ||
11.09. | Maze Therapeutics rises on $150M equity offering | 3 | Seeking Alpha | ||
11.09. | Maze Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.09. | Maze Therapeutics, Inc.: Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria ... | 209 | GlobeNewswire (Europe) | Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid... ► Artikel lesen | |
02.09. | BTIG initiates Maze Therapeutics stock with Buy rating on kidney disease potential | 1 | Investing.com | ||
02.09. | Maze Therapeutics names new finance chief | 1 | Seeking Alpha | ||
02.09. | Misbah Tahir wird neuer CFO bei Maze Therapeutics | 1 | Investing.com Deutsch | ||
02.09. | Maze Therapeutics Names Misbah Tahir As CFO | 1 | RTTNews | ||
02.09. | Maze Therapeutics, Inc.: Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer | 211 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for... ► Artikel lesen | |
02.09. | Maze Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
28.08. | Maze Therapeutics referred to federal marketing regulators over challenge brought by Vertex | 24 | FiercePharma |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ABIVAX | 71,90 | +0,84 % | EQS-News: ABIVAX: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting | EQS-News: ABIVAX
/ Key word(s): Conference
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United... ► Artikel lesen | |
CYTOKINETICS | 46,800 | +1,74 % | Cytokinetics stock maintains Buy rating as H.C. Wainwright cites exercise data | ||
REZOLUTE | 7,750 | -2,52 % | Rezolute, Inc.: Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update | REDWOOD CITY, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism... ► Artikel lesen | |
TREVI THERAPEUTICS | 8,960 | +0,11 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
CELCUITY | 44,400 | 0,00 % | Celcuity Inc.: Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program | MINNEAPOLIS, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the U.S.... ► Artikel lesen | |
PEPGEN | 4,580 | -1,08 % | Morning Market Movers: PepGen, 22nd Century Group, Immuneering, Transocean See Big Swings | OTTAWA (dpa-AFX) - At 7:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
QIAGEN | 37,695 | +0,20 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 50 Euro auf "Buy" belassen. Der Diagnostikspezialist liege mit seinen Innovationen im Bereich... ► Artikel lesen | |
EVOTEC | 6,188 | +1,94 % | adidas, Evotec, Gerresheimer, Hensoldt, TeamViewer, TUI - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
VALNEVA | 4,972 | +8,75 % | Valneva: Chikungunya-Impfstoff zeigt über vier Jahre stabile Wirksamkeit | Valneva hat neue Daten zur Antikörperpersistenz seines Chikungunya-Impfstoffs IXCHIQ veröffentlicht. Vier Jahre nach einer einmaligen Impfung zeigten nach Angaben des Biotech-Unternehmens vom Dienstag... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 7,160 | +14,65 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
BIONTECH | 83,50 | -0,18 % | BioNTech SE: BioNTech veranstaltet am 1. Oktober 2025 zweiten "AI Day" als eine Ausgabe der "Innovation Series" | MAINZ, Deutschland, 23. September 2025("InstaDeep"), am Dienstag, den 1. Oktober 2025 um 15:00 Uhr MESZ (09:00 Uhr EDT) ihren zweiten "AI Day" aus, eine Ausgabe von BioNTechs "Innovation Series"... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,805 | -2,24 % | Looking for the Next Big Pop? Here's Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce | ||
ADMA BIOLOGICS | 14,575 | -0,85 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
CRISPR THERAPEUTICS | 54,00 | -0,92 % | Morningstar Launches New Benchmark and Expands with CRSP Acquisition | ||
SCISPARC | 5,910 | +32,51 % | SciSparc Ltd: SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer | TEL AVIV, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies... ► Artikel lesen |